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• HbA1c – global efforts to standardise 
the measuring and reporting of HbA1c 
have seen this marker being included 
in the ADA criteria for the diagnosis 
of diabetes and the assessment of pre-
diabetes. 
• The gold standard for determining 
insulin resistance is the hyper-
insulinaemic euglycaemic clamp study. 
Clamp studies specifically measure 
whole body insulin-mediated glucose 
uptake under controlled conditions 
of a combined glucose and insulin 
infusion.[9] However, these tests are 
too laborious for routine use and are 
rarely used in clinical practice. Various 
mathematical models have been used to 
determine formulas to act as surrogate 
markers of insulin resistance/sensitivity 
using fasting insulin and glucose 
measurements. One that is most 
often used is the homeostatic model 
assessment (HOMA) (Table 2).
• Th e measurement of insulin is hampered 
by the fact that it is an immunoassay and 
therefore the methods used and results 
generated may vary considerably from 
one laboratory to another (owing to a lack 
of assay standardisation). 
• C-peptide – it ispart of  the pro-insulin 
precursor molecule and released in 
equimolar amounts with insulin. 
C-peptide does not infl uence plasma 
glucose levels but is utilised as a marker 
of insulin production when measured in 
conjunction with glucose levels.[8]
Dyslipidaemia 
Th e lipid profi le associated with MetS is raised 
fasting triglycerides and low concentrations 
of HDL cholesterol. Other lipoprotein 
abnormalities, e.g. increased remnant lipo-
proteins, elevated apolipoprotein B, small 
LDL particles, and small HDL particles, 
have also been documented.[7] Although 
all of these have been implicated as being 
independently atherogenic, they do not 
form part of the diagnostic criteria for MetS 
and most are not routinely measured in 
laboratories. 
Other
Microalbumin – the presence of urinary 
microalbumin is part of the WHO diagnostic 
criteria for MetS. It is measured using an 
early morning spot collection as a urine 
albumin:creatinine ratio or with a 24-hour 
urine collection and should be confi rmed 
on at least two occasions. Microalbuminuria 
is a prognostic marker for CVD, a marker 
of incipient renal disease and a marker of 
infl ammation.
C-reactive protein (CRP) – pre-diabetes and 
MetS are recognised as pro-infl ammatory 
states. Obesity is related to increased 
production of pro-infl ammatory cytokines 
and decreased production of the anti-
infl ammatory cytokine adiponectin by 
adipose tissue. Pro-infl ammatory states are 
associated with increased cardiovascular risk 
and increased CRP levels. Th e measurement 
of high sensitivity CRP (hs CRP) has been 
recommended to assist in stratifying the risk 
for CVD.[7] 
Uric acid – hyperuricaemia is commonly 
associated with MetS and has been 
postulated to play a causal role. 
Diagnostic controversies
Th e criteria for pre-diabetes and MetS 
have evolved over the years and complete 
consensus regarding the defi nitions still has 
to be reached. 
Overlap of IFG and IGT
Th ere is controversy with regard to which 
test should be performed – fasting blood 
glucose (determining IFG) or OGTT 
(determining IGT). However, since the 
OGTT is a challenge test, it is likely that 
the detection rate will be higher. Generally, 
among subjects screened using IGT, only 
20 - 25%  have FPG levels that would 
indicate impaired fasting glucose. In 
subjects screened with IFG, <50% have a 
postprandial 2-hour glucose level of ≥7.8 
mmol/l.[2]  Also, the diagnosis of subjects 
screened using the HbA1c criterion has been 
shown to not be completely consistent with 
IFG and IGT methods for the diagnosis/
screening of pre-diabetes.[9]
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Background
Vitamin D was fi rst described in the 20th 
century when a cause for the high prevalence 
Table 2. Some surrogate markers for determination of insulin resistance/
sensitivity[8] 
HOMA1-IR (insulin resistance) = (FPI* × FPG)/22.5 
HOMA1-%B (B cell function) = (20 × FPI*)/(FPG − 3.5)
Quantitative insulin sensitivity check index (QUICKI) = 1/[log(FPI) + log(FPG)]
*FPI – fasting plasma insulin.
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of rickets was sought. With the fortifi cation of 
certain foods with vitamin D, the prevalence 
of rickets decreased and little attention was 
placed on vitamin D. However, in the past 
decade there has been a revived interest in 
vitamin D, as it is thought to be associated 
with various nonskeletal disorders. Research 
has found that the prevalence of vitamin D 
defi ciency worldwide is actually much higher 
than thought, and this has led to a massive 
increase in the demand for laboratory testing 
of vitamin D levels.
Metabolism[1,2]
Vitamin D is a steroidal hormone produced 
by the skin or absorbed by the gastrointestinal 
tract (GIT). Most comes from exposure to 
sunlight, and 5 - 10 minutes of sun exposure 
2 - 3 times a week may be adequate to produce 
suffi  cient quantities of vitamin D. It is found 
in the bloodstream bound to vitamin-binding 
protein. Two hydroxylation steps occur: 
the fi rst at position 25 in the liver and the 
second in position 1 in the kidney under the 
infl uence of 1a-hydroxylase, leading to the 
formation of 1,25-dihydroxy-vitamin D or 
calcitriol, which is the active form of vitamin 
D. Th is last step is tightly regulated by factors 
such as parathyroid hormone, low phosphate 
levels and low dietary calcium intake. Fig. 1 
shows the metabolism of vitamin D.
1,25-dihydroxyvitamin D has a short half-
life of about 4 hours and 25-hydroxyvitamin 
D has a long half-life of 2 - 3 weeks. For 
this reason, even though the latter form of 
vitamin D is about 400 times less potent 
than the former, the levels are about 500 - 
1 000 times higher.
Skeletal actions[1,2]
For decades we have known of vitamin D’s 
role in maintaining healthy bones. Vitamin 
D is known to facilitate the gastrointestinal 
absorption of calcium and phosphate. Th e 
main function of 1,25-dihydroxyvitamin D 
for bone mineralisation is to maintain the 
calcium-phosphate product in the circulation, 
which allows passive mineralisation of 
collagen bone matrix. Vitamin D defi ciency 
is thus traditionally associated with 
defi ciencies of bone mineralisation, namely 
rickets in children and osteomalacia in 
adults. Before the development of the latter 
two, the decreased ionised calcium levels due 
to inadequate gastrointestinal absorption 
induce an increase in parathyroid hormone 
levels. Th is leads to the diff erentiation 
of osteoclasts and the release of calcium 
and phosphate from bone. Parathyroid 
hormone also stimulates the production of 
1,25 dihydroxyvitamin D in the kidneys. 
1,25-dihydroxyvitamin D also increases the 
expression of bone alkaline phosphatase and 
other markers of metabolism.
Non-skeletal actions
Besides the well-described skeletal eff ects 
of vitamin D, recent literature has also 
highlighted various non-skeletal eff ects of 
vitamin D. Vitamin D receptors have been 
isolated in brain, prostate, breast, colon, heart 
and immune cells and these cells respond 
directly to 1,25-dihydroxyvitamin D.[2]
Vitamin D defi ciency has been implicated 
in the pathophysiology of diabetes mellitus, 
with countries that have little sunlight, 
such as Finland, having higher incidence of 
diabetes mellitus.[3]
Early in the 20th century it was described 
that sunlight helped for auto-immune 
disorders such as lupus vulgaris and 
infectious disorders such as tuberculosis. 
Recently, vitamin D has been described to 
be anti-infl ammatory and necessary for 
antimicrobial action against intracellular 
organisms.[4] An association between low 
vitamin D levels, latitude and past sun 
exposure has also been found between 
vitamin D and multiple sclerosis,[5] 
rheumatoid arthritis and osteoarthritis.
Certain cancers, such as breast, ovarian, 
colorectal and prostate have also been 
associated with low vitamin D levels.[6] Low 
vitamin D levels have also been associated 
with hypertension, most likely via the renin-
angiotensin-aldosterone system.[7] Vitamin 
D insuffi  ciency in pregnancy is associated 
with childhood disorders such as asthma 
and autism.[8,9]  Vitamin D defi ciency has also 
been linked to schizophrenia, depression 
and  deterioration of mental function with 
age.[10] 
Deficiency and ‘desirable’ serum 
levels
Th ere is no consensus on optimal levels of 
25-hydroxyvitamin D, although experts 
defi ne defi ciency as levels of <20 ng/ml (50 
nmol/l). Vitamin D intoxication is defi ned 
as 25-hydroxyvitamin D levels >150 ng/ml 
(374 nmol/l) and is only found in individuals 
taking in excess of 40 000 IU per day. Using 
these levels, one billion people worldwide 
have vitamin D defi ciency.[2]
Certain individuals are at increased risk of 
vitamin D defi ciency:[11]
• people with pigmented skin
• those who lack exposure to sunlight
• people who wear skin-concealing garments 
or use sunscreen excessively
• children who are exclusively breast fed 
• women who have multiple pregnancies 
with short intervals
• elderly, obese or institutionalised people
• vegetarians
• people who suff er from malabsorption, 
short bowel, liver or renal disease
Fig. 1. Th e metabolism of vitamin D.
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• individuals who take certain pharmaco-
logical agents.
Vitamin D supplementation
Only few foods are a good source of 
vitamin D, namely fortified dairy products 
and breakfast cereals, fatty fish, beef liver 
and egg yolks. Besides sun exposure, the 
best way to get additional vitamin D is 
through supplementation. Traditionally, 
multivitamins contained about 400 IU of 
vitamin D, but newer ones contain 800 
- 1 000 IU. Two forms of vitamin D are 
available, namely D2 (ergocalciferol) and 
D3 (cholecalciferol). D3 is the preferred 
form, as it is more effective. As it is a fat-
soluble vitamin, it should be taken with 
meals. Corticosteroids can reduce calcium 
absorption, which impairs vitamin D 
metabolism. Lipase inhibitors such as 
Orlistat and cholestyramine may reduce 
its absorption, and phenobarbitol and 
phenytoin may increase the hepatic 
metabolism of vitamin D to inactive 
compounds and thereby decrease calcium 
absorption. Newer work has shown that 
adults may need a vitamin D intake 
exceeding 2 000 IU per day.[12]
Measurement of vitamin D
Vitamin D status is measured by 25-hy-
droxyvitamin D, as levels of 1,25-dihy-
droxyvitamin D in deficiency states may be 
normal, high or low. 25-hydroxyvitamin D 
is a better indicator of the body’s vitamin 
D reserve and is therefore the analyte of 
choice to measure in the laboratory.[1] For 
the purpose of this article, we will be refer-
ring to the measurement of 25-hydroxyvita-
min D to avoid confusion. The suggestion 
that vitamin D is associated with disease 
conditions other than calcium dysfunc-
tion, as mentioned above, has led to an in-
crease in demand for the measurement of 
vitamin D.
Vitamin D can be measured separately as 
vitamin D2 or D3 or as a total value. Vitamin 
D3 is mainly endogenously derived, and 
accounts for approximately 95% of vitamin 
D, whereas vitamin D2 is derived from food 
sources and is usually the minor fraction. 
However, with supplementation, vitamin 
D2 is given and assays that only measure 
vitamin D3 may underestimate the efficiency 
of treatment.[13] Assays that mainly measure 
a specific fraction can thus mislead the 
physician. The most important value is the 
final total value, as this represents the total 
amount of 25-hydroxyvitamin D (D2 and 
D3) in the blood. 
Previous assays were problematic, with >30% 
interlaboratory differences in results shown in 
1995.[12] This variation in results at that time led 
to Heaney stating in 2000 that ‘when ordering 
and interpreting serum 25-hydroxyvitamin 
D concentration, the physician needs, in 
virtually all cases, to ignore the laboratory’s 
published reference range…’.[14] Improvements 
in assay standardisation and the introduction 
of new automated assays for vitamin D led to 
an improvement in interlaboratory difference 
to 15% in 2011.[12]
Laboratories face various problems when 
measuring 25-hydroxyvitamin D, which 
exists in various molecular forms and is 
bound to vitamin-binding protein.[12,15] 
Reference ranges used by the laboratory 
depend on the reference population 
used, which in turn depends on season, 
altitude, latitude, age, skin colour and skin 
pigmentation, as all these factors may affect 
vitamin D levels.[2] The value also depends 
on the assay used, as standardisation has not 
yet been achieved due to methodological 
variability. This means that values may not 
be comparable between laboratories and 
may confuse clinicians.
Conclusion
Recent literature has highlighted the 
nonskeletal effects of vitamin D, which has 
led to an increase in demand for vitamin 
D assessment from the laboratory. This 
has forced the development of more rapid 
automated assays for the determination 
of vitamin D levels and attempts at 
standardisation of the assay to enhance 
clinician satisfaction and reduce confusion. 
As researchers discover more associations 
between vitamin D levels and disease, the 
demand for vitamin D measurement in 
clinical practice is bound to increase even 
further. It is therefore important that the 
clinician understands the basic physiology 
that can influence laboratory assays as 
well as the pitfalls of the assays to aid with 
interpretation of results.
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It is important to differentiate between 
food allergy and other causes of adverse 
reactions to food because patients with 
severe immediate-onset IgE-mediated food 
allergy are at risk of developing anaphylaxis 
that may cause death (Fig. 1).
Up to 35% of the population in Western 
countries self-report ‘food allergies’, but the 
true prevalence is probably between 3% and 
6% in children and 1% and 4% in adults.[1] 
Approximately 90% of documented cases 
of food allergy in the USA are caused by a 
relatively small number of foods that comprise 
cow’s milk, egg, soy, wheat, peanut, tree nuts, 
fish and shellfish. Food-induced anaphylaxis 
is caused mainly by peanut, followed by tree 
nuts, fish, cow’s milk and egg.
Laboratory investigations
Current food allergy guidelines emphasise 
that a true diagnosis of immediate-onset 
IgE-mediated food allergy requires a 
positive history of clinical allergy to a 
specific food as well as a positive allergy test 
that matches that history.[2-4]
Any investigation into food allergy has to 
commence with a detailed allergy-focused 
history and examination, followed by a 
selection of appropriate tests to confirm or 
exclude allergy. It is important to distinguish 
between sensitisation (the presence of 
allergen-specific IgE antibodies) and allergy 
(the presence of sensitisation plus clinical 
signs and symptoms of allergic reactivity). 
Skin-prick tests (SPTs) and blood allergen-
specific IgE tests measure sensitisation, 
while oral food challenge tests measure 
clinical reactivity.
Skin-prick test 
A SPT is an indirect qualitative 
measurement of IgE sensitisation. A 
positive SPT is triggered by specific 
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